Modelling the long QT syndrome with induced pluripotent stem cells

By Ilanit Itzhaki, L. Maizels, I. Huber, L. Zwi-Dantsis, O. Caspi, Aaron Winterstern, Oren Feldman, A. Gepstein, G. Arbel, H. Hammerman and 2 more. Nature, 2011

1,086 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Cellular and Molecular Neuroscience, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/d1c166e8edf5e672ccc08dc65b1979aaeaafa775

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Donald M. Bers

In Cellular and Molecular Neuroscience

1. R. Lewis
2. M. Farrer

In Molecular Biology

1. G. Daley
2. Chaomei Chen
3. Daisy A. Robinton
4. R. Jaenisch
5. A. Cheng
6. F. Soldner
7. R. Lewis
8. Susan Lindquist

Citations in the corpus

• Emerging trends and new developments in regenerative medicine: a scientometric update (2000 – 2014) (2014, methodology): “In addition to treatment applications, iPSCs have also been used to advance understanding of a variety of disorders including Alzheimer’s disease [13] and congenital long QT syndrome [14].”
• High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. (2011, background): “HUMAN-INDUCED PLURIPOTENT stem cell (hiPSC)-derived cardiomyocytes are providing new approaches to studying the cardiac cellular properties of healthy individuals and those with inheritable diseases (5, 16, 29, 49, 52).”
• Abnormal Calcium Handling Properties Underlie Familial Hypertrophic Cardiomyopathy Pathology in Patient-Specific Induced Pluripotent Stem Cells (2013, background): “…and has previously been used to model several hereditary cardiovascular disorders in vitro including dilated cardiomyopathy, LEOPARD, and long QT syndrome (Carvajal-Vergara et al., 2010; Itzhaki et al., 2011; Moretti et al., 2010; Narsinh et al., 2011a; Sun et al., 2012; Yazawa et al., 2011).”
• Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations (2011, positive): “However, so far, only a few such studies have identified disease-related phenotypes, mostly in rare, early age onset or metabolic diseases (Brennand et al., 2011; Ebert et al., 2009; Itzhaki et al., 2011; Lee et al., 2009; Marchetto et al., 2010; Rashid et al., 2010).”
• The promise of induced pluripotent stem cells in research and therapy (2012, background): “Type 2 long QT syndrome has also been modelled in cardiomyocytes, by Itzhaki and colleague”